SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT
THIS SECOND AMENDMENT, dated as of December 31, 2003 (this "AMENDMENT"), to the Second
Amended and Restated Credit Agreement, dated as of September 30, 2003 (as amended, supplemented or
otherwise modified from time to time, the "CREDIT AGREEMENT"), by and among General Electric Capital
Corporation, as Agent and Lender ("AGENT"), Inverness Medical Innovations, Inc. ("Innovations"), Wampole
Laboratories, Inc. and Inverness Medical (UK) Holdings Limited, as borrowers ("BORROWERS"), the other
Credit Parties signatory thereto, Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services
Inc., as documentation agent and co-syndication agent, UBS Securities LLC, as co-syndication agent, and the
lenders signatory thereto from time to time (collectively, the "LENDERS").
W I T N E S S E T H
WHEREAS, Borrowers have notified Agent that Borrowers and Inverness Medical Canada Inc. - Medicale
Inverness Canada Inc. ("IMC") desire that IMC become an European Credit Party to the Credit Agreement and
to cease being an Excluded Subsidiary; and
WHEREAS, Agent and Requisite Lenders have agreed to amend the Credit Agreement, in the manner, and on
the terms and conditions, provided for herein;
NOW THEREFORE, in consideration of the premises and for other good and valuable consideration, the
receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. DEFINITIONS. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in
the Credit Agreement.
2. AMENDMENT TO SECTION 9 OF THE CREDIT AGREEMENT.
(a) SECTION 9.10 of the Credit Agreement is hereby amended as of the Effective Date by adding a new sub-
paragraph (b) to read as follows and by re-lettering clauses (b) and (c) accordingly:
"(b) Without limiting the generality of sub-paragraph (a) above, for the purpose of creating a SOLIDARITE
ACTIVE in accordance with Article 1541 of the